H3N2 M2SR in Pediatric Population

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

August 15, 2018

Primary Completion Date

August 27, 2020

Study Completion Date

August 27, 2020

Conditions
InfluenzaInfluenza Immunisation
Interventions
BIOLOGICAL

Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine

Live monovalent influenza A/H3N2-based M2SR (M2 defective Single Replication vaccine), comprised of 5 out of 8 gene segments on the donor virus influenza A/Puerto Rica/8/34. HA and NA derive from an A/Brisbane/10/2007-like virus. Administered intranasally as s single dose.

OTHER

Placebo

H3N2 M2SR vaccine placebo (normal saline). Administered intranasally as a single dose.

BIOLOGICAL

Quadrivalent MDCK Inactivated Influenza Vaccine

A quadrivalent cell culture inactivated vaccine (ccIV4) is an inactivated subunit influenza vaccine prepared from virus propagated in Madin Darby Canine Kidney (MDCK) cells indicated for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. Administered intramuscularly as a single dose.

Trial Locations (1)

63104-1015

Saint Louis University - Center for Vaccine Development, St Louis

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03553940 - H3N2 M2SR in Pediatric Population | Biotech Hunter | Biotech Hunter